Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.
2.

Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review.

Rosen S, Fox MP.

PLoS Med. 2011 Jul;8(7):e1001056. doi: 10.1371/journal.pmed.1001056. Epub 2011 Jul 19. Review.

3.

Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa.

Lamb MR, El-Sadr WM, Geng E, Nash D.

PLoS One. 2012;7(6):e38443. doi: 10.1371/journal.pone.0038443. Epub 2012 Jun 7.

4.

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Fox MP, Rosen S.

Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15. doi: 10.1111/j.1365-3156.2010.02508.x. Review.

5.

Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings--a systematic review.

Govindasamy D, Meghij J, Kebede Negussi E, Clare Baggaley R, Ford N, Kranzer K.

J Int AIDS Soc. 2014 Aug 1;17:19032. doi: 10.7448/IAS.17.1.19032. eCollection 2014. Review.

6.

Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme.

Somi G, Keogh SC, Todd J, Kilama B, Wringe A, van den Hombergh J, Malima K, Josiah R, Urassa M, Swai R, Zaba B.

Trop Med Int Health. 2012 Apr;17(4):497-506. doi: 10.1111/j.1365-3156.2011.02952.x. Epub 2012 Feb 1.

7.

Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs.

Verguet S, Lim SS, Murray CJ, Gakidou E, Salomon JA.

J Infect Dis. 2013 Jan 1;207(1):72-9. doi: 10.1093/infdis/jis635. Epub 2012 Oct 24.

PMID:
23100567
8.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
9.

Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013.

Fox MP, Rosen S.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108. doi: 10.1097/QAI.0000000000000553. Review.

10.

Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821.

11.

Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.

Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, Dabis F, Pascoe M, Egger M; International Epidemiological Databases to Evaluate AIDS (IeDEA).

PLoS Med. 2009 Apr 28;6(4):e1000066. doi: 10.1371/journal.pmed.1000066. Epub 2009 Apr 28.

12.
13.

Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa.

KIDS-ART-LINC Collaboration.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):523-31. doi: 10.1097/QAI.0b013e31818aadce.

PMID:
18989227
14.

Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.

Breton G, Lewden C, Spire B, Salmon D, Brun-Vézinet F, Duong M, Allavena C, Leport C, Salamon R; APROCO COPILOTE ANRS CO8 Study Group.

HIV Med. 2007 Apr;8(3):164-70.

15.

Systematic review of retention of pediatric patients on HIV treatment in low and middle-income countries 2008-2013.

Fox MP, Rosen S.

AIDS. 2015 Feb 20;29(4):493-502. doi: 10.1097/QAD.0000000000000559. Review.

PMID:
25565496
16.

The cost-effectiveness of cotrimoxazole in people with advanced HIV infection initiating antiretroviral therapy in sub-Saharan Africa.

Abimbola TO, Marston BJ.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):e8-e14. doi: 10.1097/QAI.0b013e3182478dc0.

PMID:
22240461
17.

Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review.

Beard J, Feeley F, Rosen S.

AIDS Care. 2009 Nov;21(11):1343-56. doi: 10.1080/09540120902889926. Review.

PMID:
20024710
18.

Retention in care prior to antiretroviral treatment eligibility in sub-Saharan Africa: a systematic review of the literature.

Plazy M, Orne-Gliemann J, Dabis F, Dray-Spira R.

BMJ Open. 2015 Jun 24;5(6):e006927. doi: 10.1136/bmjopen-2014-006927. Review.

19.

Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA.

BMC Health Serv Res. 2008 Nov 20;8:241. doi: 10.1186/1472-6963-8-241.

20.

The cultural and community-level acceptance of antiretroviral therapy (ART) among traditional healers in Eastern Cape, South Africa.

Shuster JM, Sterk CE, Frew PM, del Rio C.

J Community Health. 2009 Feb;34(1):16-22. doi: 10.1007/s10900-008-9121-9.

PMID:
18923887

Supplemental Content

Support Center